News Center
A failed first IVF cycle leaves two questions on the table: whether to run another cycle, and whether to run it at the same clinic. Both answers depend on a step most guides skip entirely, the post-failure review, where you and your physician sort the outcome into embryo factors, uterine lining factors, or laboratory batch factors. Once that attribution is clear, cumulative live birth data for your age band tells you whether a second cycle still makes mathematical sense, and whether changing clinics beats changing protocols.
Most patients walk into their first consultation, complete screening labs, start stimulation medications, and absorb the cost breakdown without ever thinking about what happens if the cycle fails. Clinics prepare families for the logistics of a cycle far better than they prepare them for the morning after a negative pregnancy test. That gap costs people money, time, and sometimes their best remaining ovarian years. This guide focuses on that gap.
A failed cycle is a data-rich event. Every stage of it, retrieval yield, fertilization rate, embryo development speed, grading, and the transfer itself, generated information that a competent review should convert into a specific diagnosis. The review meeting is where that conversion either happens or gets papered over.
In a well-run program, the review happens within two to six weeks of a negative result, includes the physician who managed the cycle along with the embryology team's input, and produces written conclusions. In a poorly run one, you get a fifteen-minute phone call, a sympathetic tone, and a suggestion to "try again with a small protocol adjustment." The difference between those two experiences determines whether your next cycle is a corrected experiment or a repeat of the same one at full price.
Every failed transfer sits somewhere on a spectrum between the embryo and the uterus. Sorting out which side deserves the blame requires looking at several measurable markers, each of which points in a different direction.
Signals that point toward an embryo problem:
Signals that point toward a uterine or transfer-technique problem:
Neither list is a verdict on its own. A 35-year-old with three poor-quality embryos and a textbook-thick lining has a probable embryo problem. A 33-year-old with two PGT-A normal blastocysts that both failed has a probable receptivity question. The review should name which picture you resemble and state the evidence for it.
Embryo culture is a batch process. Eggs from one retrieval grow together in the same incubator, in the same culture media lot, handled by the same embryologist on the same day. When an entire cohort underperforms, for example twelve mature eggs producing zero usable blastocysts, the cause can sit inside the eggs, or it can sit in the conditions those eggs experienced.
Laboratory variables include culture media formulation and lot numbers, incubator gas concentrations and temperature stability, the timing and technique of insemination, and even the embryologist on duty that week. Programs track these variables internally through quality control metrics such as their blastocyst formation rate across all patients in a given period. If the lab's overall blastulation rate that month dropped, your cohort's poor outcome may reflect the batch rather than your biology.
Patients rarely hear about this because it requires the clinic to volunteer information about its own internal performance. Some programs share it readily. Others respond to a collapsed cohort with a generic statement about egg quality and an invitation to stimulate again, which quietly converts a possible lab problem into a guaranteed second bill. The question that cuts through this is direct: what was your lab's blastocyst formation rate and fertilization rate for all patients during my cycle's time window, and how does my cohort compare? A program with genuine quality control can answer this. A program that cannot, or will not, is telling you something.
Clinics differ sharply in how they handle failure, and the differences show up in specific phrases. Learning to hear them is one of the most financially protective skills a patient can develop.
| What you hear at the review | What it usually means |
|---|---|
| "Your lining looked good and the embryo was graded well, so let's just repeat the same protocol." | A reflexive retry. No new information will be generated, and the same outcome has a real chance of repeating. |
| "Three of your embryos arrested at the same stage. We reviewed the time-lapse records and the lab's monthly blastulation rate was normal, so the pattern points to gamete quality. Here is what we would change." | Genuine attribution. The clinic checked its own performance before blaming your biology, and proposes a specific change. |
| "We'd like to add a few supplements and adjust your medication doses slightly." | Ambiguous. Small dose tweaks sometimes help, but if no one explained why the cycle failed, the tweak is a guess wearing a lab coat. |
| "Given your age and this cohort's fertilization pattern, PGT-A would tell us whether the problem is chromosomal. It would also change what we recommend next." | A decision-framing answer. The clinic is offering a test whose result changes the plan, which is what medical testing is supposed to do. |
One more pattern deserves attention. Some programs delay honest attribution because attribution has consequences. Admitting a lab batch issue may create liability or reputational cost. Admitting a persistent embryo quality issue may push the patient toward a decision the clinic cannot serve, such as third-party reproduction, which means losing the revenue of another autologous cycle. This is rarely conscious misconduct. It is ordinary institutional incentive, and patients should evaluate review answers with that incentive in mind.
You are entitled to your own medical records in every U.S. state, and the embryology details of your cycle belong to you. Before the review meeting, request:
Bring this packet to any second-opinion consultation. A reviewing physician at a different clinic can often read a failed cycle's records in twenty minutes and give a sharper attribution than the original team gave in an hour, precisely because they have no incentive to protect the first clinic's narrative.
Clinics advertise per-cycle success rates. Families actually live on cumulative outcomes, the total chance of a baby across several cycles. Confusing the two numbers is the single most common analytical error patients make when deciding whether to attempt cycle two or cycle three, and it leads directly to overspending on marginal cycles whose expected value has already collapsed.
The trap works like this. Suppose a 36-year-old reads that her clinic reports a 40 percent live birth rate per transfer for her age group. She reasons that two cycles give her a strong chance and three cycles make success near-certain. The arithmetic is wrong in both directions. Per-cycle rates are not independent events, because the factors that caused cycle one to fail, egg quality, uterine factors, a difficult stimulation response, carry forward into cycle two. Meanwhile, the marginal benefit of each additional cycle shrinks while the marginal cost, financial and biological, stays constant or grows.
Public data sources make this recalculation possible without any clinic's marketing materials. The CDC publishes national assisted reproductive technology outcomes through its ART Success Rates database, and the Society for Assisted Reproductive Technology (SART) publishes clinic-specific reports broken down by age band. Both are verifiable, both are free, and both report cumulative as well as per-cycle figures. The exact numbers shift year to year, so treat any figure here as illustrative and check the current CDC and SART publications for your own calculation.
The recalculation has three steps.
Step one: find your age band's cumulative live birth curve. SART's national data and the CDC database report the chance of a live birth after one, two, and three complete cycles for each age group. For patients under 35, the cumulative curve keeps climbing meaningfully through the third cycle. For patients around 40 and above, the curve flattens early, because egg aneuploidy rates rise steeply with age and no number of repetitions fixes a chromosomal problem in the eggs themselves.
Step two: compute the marginal gain of the next cycle. If the cumulative chance after two cycles is, illustratively, 55 percent and after three cycles is 63 percent, the third cycle adds 8 percentage points. That 8-point gain is the honest denominator for your decision. Compare it against the full cost of a cycle, which in the United States typically runs in the five-figure range per cycle before medications, with wide variation by region and program, so confirm current pricing directly with any clinic you are considering.
Step three: adjust the curve for what your failed cycle revealed. Population curves assume a typical patient. Your failed cycle generated individualized evidence that the population lacks. A 36-year-old whose first cycle produced four euploid blastocysts from a strong cohort sits well above her age band's curve. A 36-year-old whose first cycle produced one poor-quality blastocyst from twelve mature eggs sits well below it, because her ovarian response and embryo development profile resemble older bands more than her own. The review meeting's attribution, embryo problem versus receptivity problem versus lab problem, tells you which direction to shift.
| What cycle one showed | Direction to shift from the population curve | What it implies for cycle two |
|---|---|---|
| Multiple euploid blastocysts still frozen; transfer failed | Upward. The expensive, uncertain part is done; remaining transfers are comparatively cheap attempts. | Strong case for transferring remaining embryos before any new stimulation, and for receptivity testing after repeated euploid failures. |
| Poor fertilization and arrest across the cohort; no euploid embryos | Downward, unless the review found a lab batch explanation. | A second identical cycle has low marginal value. Change something structural, protocol, lab, or gamete strategy, or reconsider continuing. |
| Few eggs retrieved despite high doses; review confirms diminished ovarian reserve trajectory | Downward and time-sensitive. | Marginal gains shrink with each passing month. Decisions carry more urgency than the population curve suggests. |
| Good cohort, good embryos, first failed transfer, no prior failures | Roughly on-curve. One failed transfer of a good embryo is statistically ordinary. | Continuing is usually rational; demand only a clear explanation of what, if anything, will differ. |
Changing protocols inside the same program makes sense when the review produced a specific, mechanistic explanation and the program has the tools to act on it. Switching programs makes sense under different conditions, and patients often stay too long because switching feels like abandoning a team that already knows their history. The records transfer in a week or two; the knowledge is portable.
Consider switching programs when several of these apply:
Conversely, staying makes sense when the failure was a single transfer of a good embryo, when the review was specific and credible, and when the proposed changes for cycle two follow logically from the attribution. Loyalty to a program that has earned it is rational. Loyalty to a program that keeps saying "let's try again" without explanation is expensive.
Before committing to cycle two anywhere, ask the team to complete this sentence with specifics: because cycle one failed for reason X, cycle two will differ in the following concrete ways, and here is what each change is expected to fix. A real strategy change names the mechanism. Adding a medication without naming the mechanism it addresses is a cosmetic change. Legitimate differences include moving from a fresh to a fully frozen transfer plan, adding PGT-A when embryo quality was ambiguous, altering the stimulation approach to change egg yield versus egg quality balance, testing and treating receptivity after repeated euploid failures, or changing the insemination method when fertilization was the weak link. If the answer to "what will be different" is only a dose adjustment, you have learned that the clinic has no attribution and no plan, which is itself the most important finding of the entire review.
Programs that treat failed cycles as diagnostic events tend to share structural features: in-house embryology labs with tracked quality metrics, physicians who personally review the cycle's time-lapse and grading data, and a willingness to tell patients when the data points away from further autologous attempts. Several large U.S. groups operate this way, and their scale matters here for a specific reason, high cycle volume gives their labs enough internal data to detect batch problems quickly and to answer the question about lab-wide blastulation rates in your cycle window.
CCRM Fertility, headquartered in Colorado with locations across multiple states, has built its clinical model around repeat-failure and complex cases, with an in-house laboratory science program and physicians who frequently take over patients whose first cycles failed elsewhere. Patients arriving with a completed failed cycle fit squarely within the case profile the group is structured to handle.
RMA (Reproductive Medicine Associates), with its flagship network in the New York area and affiliated sites in other states, runs high-volume laboratories with extensive PGT experience, and its physicians publish and practice within a data-heavy, protocol-comparison culture. For patients whose failed cycle left ambiguous embryo quality questions, a program accustomed to large PGT datasets has more context for judging whether a cohort's outcome was unusual.
Shady Grove Fertility, based in Maryland with dozens of offices across multiple states, operates at a volume that supports structured review processes and shared decision-making tools, and it has historically offered outcome-based financial arrangements for multi-cycle commitments, which changes the marginal-cost arithmetic described above. Patients weighing a second or third cycle should ask any program, this one included, exactly what its shared-risk or multi-cycle products do and do not cover, since the fine print determines whether the arrangement actually protects against the scenario of repeated failed transfers.
Success rates, cycle volumes, and pricing vary by location and reporting year for every program named here. The current SART clinic reports and the CDC ART database list each clinic's most recent verified outcomes by age band, and any figure a clinic quotes verbally should be checked against those public filings before you rely on it.
Several predictable errors recur at this decision point, and each one has a straightforward correction.
The weeks after a failed cycle are the worst possible time to make a fully reasoned financial decision, and the review meeting is best scheduled with that in mind. Give yourself a defined pause, commonly two to four weeks, before committing to a next cycle, and use the pause to complete three tasks: obtain the complete records packet, complete the review meeting, and pull the current CDC or SART cumulative figures for your age band. Decisions made after those three tasks are consistently better than decisions made in the first week of grief.
Practical care during the pause matters as well. Bleeding and hormonal withdrawal after a failed cycle are physically normal, though any severe pain, heavy bleeding, or fever warrants a call to the clinic, since ovarian hyperstimulation recovery or, rarely, infection can complicate the post-cycle weeks. Sleep, moderate exercise, and limiting exposure to pregnancy announcements and fertility social media content all have documented effects on distress levels in this population, per research on psychological outcomes in fertility treatment. Most reputable programs offer or refer to counselors experienced in reproductive loss, and using that resource is standard care rather than a sign of poor coping.
Financially, request an itemized quote for the proposed next cycle before committing, and ask specifically which components, monitoring, retrieval, anesthesia, culture, PGT, transfer, and cryostorage, are bundled and which bill separately. Reputable programs provide this without friction, and the itemization lets you compare the marginal cost of cycle two against the marginal benefit you calculated from the cumulative curves.
Compress the whole process into four moves. First, get the records, every fertilization number, development note, and grade, because decisions made on memory are decisions made on noise. Second, force a specific attribution at the review meeting, and treat a refusal to attribute as a finding in itself. Third, rerun the math using cumulative live birth data for your own age band, adjusted upward or downward by what your cycle revealed, so the next cycle's marginal cost gets weighed against its true marginal benefit. Fourth, decide whether the fix is a protocol, a program, or a stop, and let the attribution answer that question rather than letting hope or sunk cost answer it for you.
Patients who run this sequence rarely regret the outcome, whichever direction it points. Patients who skip it frequently spend their second and third cycles rediscovering what their first cycle already knew.
Verifiable sources for the figures discussed: the CDC ART Success Rates database (cdc.gov/art) for national outcomes by age band, and SART clinic reports (sart.org) for clinic-specific, age-stratified cumulative and per-cycle results. All success rates, volumes, and prices referenced in general terms in this article shift by year and program; confirm current figures through those public databases and through each clinic's official published information before making treatment or financial decisions.
